Epsilon HealthcareASX:EPN +4.55% PS Ratio is 0.96 as of Jul. 02, 2026, which is 42% below its 10-year median of 1.66. The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, Epsilon Healthcare ranks better than 76.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Epsilon Healthcare's share price is A$0.023.
Epsilon Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.02. Hence, Epsilon Healthcare's PS Ratio for today is 0.96.
Good Sign:
Epsilon Healthcare Ltd stock PS Ratio (=0.88) is close to 2-year low of 0.8.
The historical rank and industry rank for Epsilon Healthcare's PS Ratio or its related term are showing as below:
ASX:EPN'
s PS Ratio Range Over the Past 10 Years
Min: 0.46 Med: 1.66 Max: 45.68
Current: 0.96
During the past 9 years, Epsilon Healthcare's highest PS Ratio was 45.68. The lowest was 0.46. And the median was 1.66.
ASX:EPN's PS Ratio is ranked better than 76.63% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs ASX:EPN: 0.96
Epsilon Healthcare Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Epsilon Healthcare was 56.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -12.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -13.60% per year.
During the past 9 years, Epsilon Healthcare's highest 3-Year average Revenue per Share Growth Rate was 26.00% per year. The lowest was -20.60% per year. And the median was -5.70% per year.
Back to Basics: PS Ratio
Epsilon Healthcare (ASX:EPN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Epsilon Healthcare PS Ratio Related Terms
Epsilon Healthcare PS Ratio Historical Data
* Premium members only.
The historical data trend for Epsilon Healthcare's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Epsilon Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epsilon Healthcare PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Epsilon Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where Epsilon Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Epsilon Healthcare's Share Price of today is A$0.023.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epsilon Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Epsilon Healthcare (ASX:EPN) has a PS Ratio of 0.96 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Epsilon Healthcare and its competitors. This is 42% below median its historical median of 1.66. Over the past decade, Epsilon Healthcare's PS Ratio has ranged from 0.46 to 45.68. According to the industry distribution chart, Epsilon Healthcare ranks #222 out of 950 companies in the Drug Manufacturers industry, placing it in the top 23.4%.
Is Epsilon Healthcare's PS Ratio too high?
Epsilon Healthcare's current PS Ratio of 0.96 is 42% below median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 45.68. The Drug Manufacturers industry median PS Ratio is 2.27. Epsilon Healthcare's value of 0.96 is 57.7% below this industry median. Based on the distribution chart, Epsilon Healthcare ranks #222 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Epsilon Healthcare's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Epsilon Healthcare ranks #222 out of 950 companies for PS Ratio. This places Epsilon Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.27. Epsilon Healthcare's value of 0.96 is 57.7% below this benchmark. Historically, Epsilon Healthcare's own PS Ratio has ranged from 0.46 to 45.68 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 2.27, Epsilon Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epsilon Healthcare's current PS Ratio of 0.96 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Epsilon Healthcare and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epsilon Healthcare's current PS Ratio is 0.96, which is 42% below median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Epsilon Healthcare (ASX:EPN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 23.3% below its estimated fair value. The current PS Ratio is 0.96, which is 42% below median its 10-year median of 1.66 and 57.7% below the Drug Manufacturers industry median of 2.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current PS Ratio is 0.96 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPN has been successfully added to your 